Relax HCIT… We aren’t members of that exclusive

New Post Public Reply Private Reply Replies (1) Message Board
Goosebumps HCIT #110022
714
Relax HCIT…

We aren’t members of that exclusive group of big Pharma yet… and I say yet.

It doesn’t mean we will not ever become members of the club. There apparently is some prerequisites we need to have in place first to achieve that membership. You’re guess is as good as mine on what we absolutely need but to me it revolves around money… and enough money to be able to jump through all the hoops.

When Frodo steered us to Brazil he gave our little company new life and that was a huge change for us to go international and not accepting the challenges of only the FDA . With being pushed off time after time with things they would like to see. Making it seem like it was a planned delay of our BLA for Duel HIV. I feel we will get more of a fair shake in Brazil or any other country than we do here at home in the USA.

If you look at the possibilities now and see how an approval works for us in Brazil and then the following countries with a domino effect… then we can judge our potential for revenue enough to maybe physically push our way into the US market with the much needed monies to do it right and quickly. Because I believe it only takes money and lots of it to get our trials done here in faster more realistic timelines.

Right now the majority of the patients are still trying big pharmas drugs instead of our and big Pharma pays more to get those patients. We have a hard time competing with other drugs not because we can’t save lives but because the money machine is beating us down. This is what I believe the biggest issue. Money/revenue is everything.

When we have more money to put towards trials and acquiring patients we will level the playing field. Then after a few approvals we won’t be that red headed step child any longer. ( I had those red highlights… so it’s personal) We will have come of age as a company and our approvals will come fast and often. How can we argue that we will not become a platform drug? Just have faith in our management for the direction they chose and see why it was the right choice considering the challenges we faced here.

Being an optimist is hard sometimes but seeing the potential for this company is very easy. Seeing the challenges is the problem with a moving target. I see so many shots on goal. Having 5 possible BTD’s in the next 6 months maybe 2 EUA’s just gives us the great odds of an approval or two before the end of 2022. Some could happen much sooner. I am a believer and will not let people like Craig poo poo on the possibilities with his negative perceptions and his attacks on our companies management. So we are doing just fine. We all have to realize that we have a champagne drug that we are trying to get across a finish line on a beer budget. It makes it tough. This is why we need to finance our 200 million shares so we can continue our path to success. It’s not only something we should do it’s something we have to do. The other options are far to risky. I am not a big fan of taking the risky way. Putting myself in the position of failure when we don’t have to. So voting the company line of everything they asked for is the best path. The one we need if we really want success.

When I use Frodo as a nickname for Nader I use it as a compliment. The protector our our precious Leronlimab… our precious…

file:///var/mobile/Library/SMS/Attachments/64/04/6FEB32D5-8821-4443-AA6C-A5DE15ED8A07/IMG_3422.JPG

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

White House Photographer Reveals Unseen Historic Moments

Updated Category News Views 94

You don’t just wander into the White House and leave unimpressed, not if you're someone who lived it like David Hume Kennerly. Imagine stepping behind those gates and through history's lens, capturing moments few had the privilege to see. Kennerly's debut as the Chief White House Photographer was at a turning point in America, just after the Nixon saga collapsed in...

Continue Reading
Boardwalk Welcomes New CFO: What This Means for Growth

Updated Category News Views 77

Boardwalk's Leadership Shift: Enter Scott Wexler Nothing spices up a pipeline company's menu like a fresh plate of leadership. Boardwalk Pipelines, out in Houston, just handed the keys to their finance dungeon over to Scott Wexler. He's stepping in as the chief financial officer and senior VP of corporate strategic development, an upgrade that got announced today. Packing...

Continue Reading
EzAccounting: Your Q3 IRS Filing Gets a No-Nonsense Tool

Updated Category News Views 19

Taking Tax Deadlines Head-On Tax season's got businesses sweating all over the country, but it doesn't have to be a full-scale panic attack if you've got the right gear. That's where ezAccounting steps in, dishing out a reliable solution to hit those looming IRS Form 941 deadlines without a migraine. By November 2, 2026, companies are looking to dodge the bullet of...

Continue Reading
Markel's Reinsurance Shift with $4.8B Deal: Strategic Move?

Updated Category News Views 29

Weaving Through Complex Insurance Terrain When Markel Insurance pulls a move on the chessboard that involves $4.8 billion in subject reserves, we better pay attention. The insurance bigwig has inked a reinsurance deal with Enstar. This plan, they say, will help them focus more on their specialty insurance game while tidying up the loose ends in their global reinsurance...

Continue Reading
LUNGevity's Bold $1M Bet on Lung Cancer Research

Updated Category News Views 24

Investing in the Future of Lung Cancer Research Damn, you don't see this kind of commitment every day! LUNGevity Foundation is dropping over a million bucks on the table to swell the ranks of lung cancer researchers. They're not just tossing dollars at established players; they're betting on fresh minds to shake things up in this critical field. Tackling lung cancer isn't...

Continue Reading
Pave and Levels.fyi Unite: Revolutionize Pay Decisions

Updated Category News Views 17

Diving straight into the heart of it, here's a move in the business world that's all but marking its territory on the compensation landscape. Pave, already a big player in agentic compensation management, is shaking hands with Levels.fyi, a platform prized for its real-deal compensation data detailed down to the company, level, location, and skill. These folks are...

Continue Reading
Navigating Gas-to-AI Power: Challenges & Opportunities

Updated Category News Views 19

Natural Gas Abundance Meets Conversion Hurdles It’s a wild scene when you've got oodles of natural gas but struggle to get it into AI data centers. That’s the picture today: U.S. gas production hitting a high of 137 billion cubic feet daily, while converting that gas into practical energy is the real challenge. You see, the gas market is ready to rumble, ticking...

Continue Reading
Aktia Bank: Steady Ratings, Focused Expansion in Europe

Updated Category News Views 67

Aktia's Ratings Get a Boost In the world of financial minutiae, it was S&P Global Ratings that took the stage, buzzing about Aktia Bank Plc. The bank just had its ratings held steady with an outlook lift from negative to stable. That's like someone throwing you a life jacket when you're treading water; significant if you're trying to stay afloat, not so much if you've got...

Continue Reading
Fed Holds Steady, But CD Rates Climb: Savers' Edge

Updated Category News Views 37

The Fed Sits Tight, But CD Rates Surge Isn't it a kicker when the Fed holds rates steady, yet the CD market is buzzing like a crowded trading floor on a bull run? We've seen the Federal Reserve hold its ground without budging interest rates, keeping everyone guessing while inflation's still a shadow in the corner. But the star of the show here isn't the Fed's poker...

Continue Reading
Rothera's KPI Swap Approval: A Financial Game Changer

Updated Category News Views 107

Revolutionizing Risk Management with KPI Swaps Boy, if there's one thing that gets my ticker going, it's the buzz of innovation in financial markets. Rothera just landed a CFTC stamp of approval for something that's about to shake up how institutional traders manage risk: Key Performance Indicator (KPI) swaps. And can you believe it? This isn't just another derivative...

Continue Reading

Top 5 Most Recently Viewed Articles

Kenmare Resources Shares Insights on WCP A Project Progress

Updated Category News Views 200

Kenmare Resources Offers Insights on Wet Concentrator Plant A Kenmare Resources plc, a prominent player in the global titanium minerals and zircon market, recently provided important updates on its Wet Concentrator Plant A upgrade project. This facility plays a critical role in the company’s operational excellence and future growth. Progress on the Upgrades Under the...

Continue Reading
Aging at Home: The Real Costs and Obstacles Ahead

Updated Category News Views 38

Facing the Realities of Aging In Place Alright, let's talk straight. Everyone dreams of staying home in their twilight years, kicking back in their favorite chair with family nearby. But the harsh truth? That comfort comes with a price tag. According to Northwestern Mutual's 2026 Planning & Progress Study, up to 83% of Boomers+ and most other generations fancy the idea of...

Continue Reading
Evaluating Health Stocks: UnitedHealth, CVS, and Cigna's Resilience

Updated Category News Views 225

Introduction: A Closer Look at Health Stocks The Federal Trade Commission (FTC) is currently examining the pharmacy benefit managers (PBMs) of leading companies like UnitedHealth Group Inc (NYSE: UNH), CVS Health Corp (NYSE: CVS), and Cigna Group (NYSE: CI). This scrutiny raises questions for investors about which of these healthcare giants can weather the impending...

Continue Reading
HUB24 Reports Record Inflows, Shares See Significant Surge

Updated Category News Views 274

HUB24 Reports Major Quarterly Growth The wealth management platform HUB24 Ltd (ASX: HUB) has made headlines recently, witnessing a significant surge in its share price. The increase came after the company shared impressive quarterly net inflows, alongside revealing ambitious strategic plans. Record Quarterly Net Inflows HUB24 announced that it achieved record platform net...

Continue Reading
Gabelli Global Trust Announces Ongoing Monthly Distributions

Updated Category News Views 116

Gabelli Global Utility & Income Trust Sustains Monthly Cash Distributions The Gabelli Global Utility & Income Trust (NYSE American: GLU) has reiterated its commitment to providing consistent monthly distributions to its shareholders. This initiative underscores the Trust's ongoing strategy aimed at delivering robust financial returns while focusing on tax-advantaged...

Continue Reading